|
Age, years
|
|
Average
|
54.7
|
|
Median
|
55.5
|
|
Range
|
30–80
|
|
Gender
|
|
Male
|
42
|
29.6
|
|
Female
|
100
|
70.4
|
|
Cancer Type
|
|
Breast Cancer
|
73
|
51.4
|
|
Colorectal Cancer
|
69
|
48.6
|
|
Treatment Setting
|
|
Neoadjuvant
|
19
|
13.4
|
|
Adjuvant
|
80
|
56.3
|
|
Metastatic/Palliative
|
43
|
30.3
|
|
Prior Chemotherapy Exposure
|
|
Chemotherapy Naïve
|
17
|
12.0
|
|
Prior Chemotherapy Exposure
|
125
|
88.0
|
|
Pre-Chemotherapy Testing Timing
|
|
Same day as chemotherapy
|
106
|
74.6
|
|
Day prior to chemotherapy
|
36
|
25.4
|
|
Antineoplastic Regimen Used
|
|
Breast Cancer Regimens
|
|
5-Fluorouracil/Epirubicin/Cyclophosphamide (FEC)
|
21
|
14.8
|
|
Docetaxel (D)
|
21
|
14.8
|
|
Docetaxel/Cyclophosphamide (DC)
|
14
|
9.9
|
|
Paclitaxel (P)
|
11
|
7.7
|
|
Docetaxel/Carboplatin (DCARB)
|
4
|
2.8
|
|
Doxorubicin/Cyclophosphamide (AC)
|
2
|
1.4
|
|
Colorectal Cancer Regimens
|
|
5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX)
|
45
|
31.7
|
|
5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI)
|
11
|
7.7
|
|
Capecitabine/Oxaliplatin (CAPOX)
|
9
|
6.3
|
|
5-Fluorouracil/Leucovorin (FUFA)
|
2
|
1.4
|
|
Irinotecan
|
2
|
1.4
|
|
Additional Antineoplastic Medications Used
|
|
Trastuzumab
|
16
|
11.3
|
|
Bevacizumab
|
12
|
8.5
|
|
Pertuzumab
|
2
|
1.4
|
|
Panitumumab
|
2
|
1.4
|
|
Supportive Medications Used
|
|
Steroids
|
142
|
100.0
|
|
Benzodiazepinesa
|
0
|
0.0
|
|
Diphenhydramine
|
54
|
38.0
|
